Arachnova Therapeutics

Arachnova was a pioneering biotechnology company based in Cambridge, UK, focused on the systematic repositioning of existing drugs for new therapeutic indications. Founded in 1998 by Dr. David Cavalla, the firm utilized a proprietary informatics-driven platform to identify novel uses for small molecules that had already passed initial safety hurdles. The company's pipeline targeted a variety of conditions, including functional dyspepsia, neuropathic pain, and sleep disorders. Arachnova successfully advanced several programs into Phase 2 clinical trials, demonstrating the commercial and clinical viability of its drug repurposing strategy. Although the company is no longer active, its approach significantly influenced the modern drug repositioning landscape and the development of value-added medicines.